Jonggi Choi, MD; Hyo Jeong Kim, MPH; Jayoun Lee, PhD; et al.
free access
JAMA Oncol. 2019;5(1):30-36. doi:10.1001/jamaoncol.2018.4070
This cohort study uses data from the Korean National Health Insurance Service database to compare the risk of hepatocellular cancer associated with entecavir vs tenofovir disoproxil fumarate in patients receiving long-term treatment for chronic hepatitis B infection.
Po-Hong Liu, MD, MPH; Kana Wu, MD, MPH, PhD; Kimmie Ng, MD, MPH; et al.
free access
JAMA Oncol. 2019;5(1):37-44. doi:10.1001/jamaoncol.2018.4280
This cohort study of women in the Nurses鈥� Health Study II assesses the association of obesity and weight gain since early adulthood with early-onset colorectal cancer.
Aman U. Buzdar, MD; Vera J. Suman, PhD; Funda Meric-Bernstam, MD; et al.
free access
JAMA Oncol. 2019;5(1):45-50. doi:10.1001/jamaoncol.2018.3691
This phase 3 randomized clinical trial compares disease-free and overall survival among patients with operable HER2-positive breast cancer who received concurrent vs sequential administration of neoadjuvant chemotherapy.
Hsiao-Mei Lu, PhD; Shuwei Li, PhD; Mary Helen Black, PhD; et al.
free access
JAMA Oncol. 2019;5(1):51-57. doi:10.1001/jamaoncol.2018.2956
This study of patients with breast cancer, ovarian cancer, or both compared with controls uses whole-exome sequencing to investigate whether non-BRCA genes are associated with an increased risk of those cancers.
-
Invited Commentary
Hereditary Breast and Ovarian Cancer Testing in the Genomic Era
Stephanie L. Greville-Heygate, MSc; Diana M. Eccles, MD; Lucy E. Side, MD, MRCP
JAMA Oncol
Justin G. Trogdon, PhD; Aaron D. Falchook, MD; Ramsankar Basak, PhD; et al.
free access
JAMA Oncol. 2019;5(1):60-66. doi:10.1001/jamaoncol.2018.3701
This large cohort study uses the SEER-Medicare database to evaluate the Medicare costs associated with diagnosis and treatment of nonmetastatic prostate cancer in men 70 years or older.
Erminia Massarelli, MD; William William, MD; Faye Johnson, MD, PhD; et al.
free access
JAMA Oncol. 2019;5(1):67-73. doi:10.1001/jamaoncol.2018.4051
This phase 2 clinical trial examines whether the efficacy of nivolumab is amplified through treatment with ISA 101, a synthetic long-peptide human papillomavirus 16 vaccine, in patients with incurable human papillomavirus 16鈥損ositive cancer.
Leisha A. Emens, MD, PhD; Cristina Cruz, MD; Joseph Paul Eder, MD; et al.
free access
JAMA Oncol. 2019;5(1):74-82. doi:10.1001/jamaoncol.2018.4224
This phase 1 study evaluates the safety, clinical activity, and biomarkers associated with the use of single-agent atezolizumab in women with metastatic triple-negative breast cancer.
Jaafar Bennouna, MD; Sandrine Hiret, MD; Aurelie Bertaut, PhD; et al.
free access
JAMA Oncol. 2019;5(1):83-90. doi:10.1001/jamaoncol.2018.4465
This open-label, randomized phase 2 trial evaluates progression-free survival with chemotherapy plus bevacizumab vs cetuximab among patients with progression of metastatic colorectal cancer (mCRC) after bevacizumab plus chemotherapy.
George B. Hanna, FRCS, PhD; Piers R. Boshier, MRCS, PhD; Sheraz R. Markar, MRCS, PhD; et al.
free access
online only
JAMA Oncol. 2019;5(1):e182815. doi:10.1001/jamaoncol.2018.2815
This systematic review and meta-analysis examines the diagnostic accuracy of volatile organic compound (VOC)鈥揵ased exhaled breath tests for cancer and the challenges and strategies inherent in the use of breath testing for cancer diagnosis.
Gerald Falchook, MD; Robert L. Coleman, MD; Andrzej Roszak, MD; et al.
free access
online only
JAMA Oncol. 2019;5(1):e183773. doi:10.1001/jamaoncol.2018.3773
This phase 1 and 2 clinical trial examines progression-free survival in patients with ovarian or breast cancer treated with alisertib in combination with paclitaxel vs paclitaxel alone.